An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers
Technology in Cancer Research & Treatment · 2023
DOI: 10.1177/15330338231180785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2023. Verfasst von Yajiao Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine, Jiangnan University, Wuxi, China. Hauptthemen laut MEDLINE: Nomograms, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Systemic inflammatory indicators are clinically significant in guiding diffuse large B-cell lymphoma (DLBCL) prognosis. However, which inflammatory markers are the best predictors of DLBCL prognosis is still unclear. In this study, we aimed to create a nomogram based on the best inflammatory markers and clinical indicators to predict the overall survival of patients with DLBCL. Patients and methods: We analyzed data from 423 DLBCL patients from two institutions and divided them into a training set, an internal validation set, and an external validation set (n = 228, 97, and 98, respectively). The least absolute shrinkage and selection operator and Cox regression analysis were used to develop nomograms. We assessed model fit using the Akaike information criterion and Bayesian information criterion. The concordance index (C-index), calibration curve, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA) were used to assess the nomogram's predictive performance and clinical net benefit and compared with the International Prognostic Index (IPI) and National Comprehensive Cancer Network (NCCN)-IPI.
Results
The inclusion variables for the nomogram model were age, Eastern Cooperative Oncology Group performance status, lactate dehydrogenase level, the systemic immune-inflammation index (SII), the prognostic nutritional index (PNI), and β-2 microglobulin (β-2 MG) level. In the training cohort, the nomogram showed better goodness of fit than the IPI and NCCN-IPI. The C-index of the nomogram (0.804, 95% CI: 0.751-0.857) outperformed the IPI (0.690, 95% CI: 0.629-0.751) and NCCN-IPI (0.691, 95% CI: 0.632-0.750). The calibration curve, ROC curve, and DCA curve analysis showed that the nomogram has satisfactory predictive power and clinical utility. Similar results were found in the validation cohort.
Conclusion
The nomogram integrated with the clinical characteristics and inflammatory markers is beneficial to predict the prognosis of patients with DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wuxi School of Medicine, Jiangnan University, Wuxi, China.
- Department of Hematology, Affiliated Hospital of Jiangnan University, Wuxi, China.
- Institute of Integration of Traditional Chinese and Western Medicine, Affiliated Hospital of Jiangnan University, Wuxi, China.
ORCID-Profile: Yajiao Liu
Zitieren
APA
Liu, Y., Sheng, L., Hua, H., Zhou, J., Zhao, Y., & Wang, B. (2023). An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338231180785
Vancouver
Liu Y, Sheng L, Hua H, Zhou J, Zhao Y, Wang B. An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers. Technology in Cancer Research & Treatment. 2023. doi:10.1177/15330338231180785
BibTeX
@article{Liu2023,
author = {Liu, Yajiao and Sheng, Li and Hua, Haiying and Zhou, Jingfen and Zhao, Ying and Wang, Bei},
title = {An Externally Validated Nomogram for Predicting the Overall Survival of Patients With Diffuse Large B-Cell Lymphoma Based on Clinical Characteristics and Systemic Inflammatory Markers},
journal = {Technology in Cancer Research & Treatment},
year = {2023},
doi = {10.1177/15330338231180785}
}
EUVIMED